Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca and Sanofi’s Beyfortus approved in China

January 2, 2024
Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi

AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …

News

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager

January 2, 2024
Research and Development Astellas, Cancer, Elpiscience, Oncology, bispecific macrophage

Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration and license agreement for novel …

News

Calliditas Therapeutics gains FDA approval of Tarpeyo

December 22, 2023
Medical Communications Calliditas, FDA, Nephrology, kidneys

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …

News

FDA approves AstraZeneca and Ionis’s Wainua

December 22, 2023
Medical Communications AstraZeneca, FDA, Ionis, Neurology, Wainua

AstraZeneca and Ionis have announced that the US Food and Drug Administration (FDA) has approved Wainua (eplontersen) for the treatment …

News

Ocelot Bio gains FDA ODD for OCE-205 for ascites treatment

December 21, 2023
Research and Development Gastrointestinal tract, Ocelot Bio, ascites

Ocelot Bio has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to OCE-205 …

News

Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial

December 21, 2023
Research and Development ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial

Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 …

News

Gilead and Compugen enter exclusive license agreement for immunotherapy programme

December 20, 2023
Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology

Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …

News
markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023
Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …

News

BioNTech achieves milestone at vaccine manufacturing site in Rwanda

December 19, 2023
Manufacturing and Production BioNTech, Immunology, manufacturing, rwanda

BioNTech has announced that it has reached the next milestone in the establishment of its mRNA vaccine manufacturing capacities in …

News

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

News

GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment

December 18, 2023
Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer

GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …

News

InnoCare shares results from phase 2 trial for atopic dermatitis treatment

December 18, 2023
Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial

InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …

News

FDA approves Glaukos’ iDose TR treatment for glaucoma disease

December 15, 2023
Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma

Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …

News

First patient dosed in Cullinan Oncology’s phase 1 trial for CLN-617

December 15, 2023
Research and Development Cullinan Oncology, Oncology, clinical trial, tumours

Cullinan Oncology has announced that the first patient has been dosed with CLN-617 in its phase 1 clinical trial, designed …

News

FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment

December 14, 2023
Medical Communications FDA, Mission Therapeutics, Nephrology, acute kidney injury, clinical trial

Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application …

News

FDA grants Kyverna Therapeutics fast track designation for myasthenia gravis treatment

December 14, 2023
Medical Communications FDA, Kyverna Therapeutics, Musculo-skeletal disorder, myasthenia gravis

Kyverna Therapeutics has announced that it has gained fast track designation from the US Food and Drug Administration (FDA) for …

News

Merck and Moderna initiate phase 3 study of NSCLC treatment

December 13, 2023
Medical Communications Merck, Moderna, NSCLC, Oncology, clinical trial

Merck (known as MSD outside of the US and Canada) and Moderna have announced the initiation of the phase 3 …

News
milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023
Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …

News

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

News

AstraZeneca to acquire Icosavax for up to $1.1bn

December 12, 2023
Business Services AstraZeneca, Icosavax, Immunology, acquisition, immunology, vaccines

AstraZeneca has announced that it has entered into a definitive agreement to acquire Icosavax for approximately $15 per share or …

News
The Gateway to Local Adoption Series

Latest content

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026

Medicus Pharma’s Teverelix shows positive efficacy and safety in premenopausal women

January 13, 2026